One-third of IBD patients do not undergo objective assessment, TDM

Approximately one-third of patients who underwent either a biologic dose change or discontinuation did not undergo objective disease activity assessment or therapeutic drug monitoring before therapy was altered, according to data from Digestive Disease Week.“Enhanced understanding of the reason for failure or need for those changes in patients on those biologics may help us optimize our biologic regimen and outcomes for patients with Crohn’s disease and ulcerative colitis,” Benjamin H. Click, MD, MS, gastroenterologist at Cleveland Clinic, told Healio Gastroenterology. “[When]Read More

Share on facebook
Share on twitter
Share on linkedin